Ardelyx Announces Participation in Upcoming Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ: ARDX), a biopharmaceutical company committed to discovering, developing, and commercializing innovative, first-in-class medicines aimed at satisfying significant unmet medical needs, has revealed its participation in several upcoming investor conferences.

Investment Opportunities

One of the key events is the Leerink Partners 2025 Global Healthcare Conference, which will take place in Miami, Florida. Ardelyx is scheduled to present on Tuesday, March 11 at 8:00 a.m. ET. Additionally, one-on-one meetings will also be held on the same day.

Investors interested in accessing the live webcast of Ardelyx's presentation can visit the Events and Presentations page on the Ardelyx website at ir.ardelyx.com. A replay of this presentation will be made available for 30 days post-event.

More Conferences Ahead

Additionally, Ardelyx will participate in the Jefferies Biotech on the Beach Summit in Miami. One-on-one meetings are scheduled for Wednesday, March 12.

Another significant event is the Barclays 27th Annual Global Healthcare Conference, also occurring in Miami. Ardelyx will be partaking in a fireside chat on Thursday, March 13 at 10:00 a.m. ET, with one-on-one meetings following throughout the day.

Similar to the previous event, a live webcast of the Barclays fireside chat can be accessed on the Ardelyx Events and Presentations page at ir.ardelyx.com. A 30-day replay will also be available.

About Ardelyx, Inc.

Ardelyx was established with the clear goal of discovering, developing, and commercializing first-in-class medications that address critical medical needs. The company currently has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has also formed agreements to develop and market tenapanor outside the U.S. Kyowa Kirin is responsible for the commercialization of PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. Furthermore, a New Drug Application for tenapanor targeting hyperphosphatemia has been submitted in China in partnership with Fosun Pharma. In Canada, Knight Therapeutics is responsible for marketing IBSRELA.

For more information about Ardelyx, visit ardelyx.com and connect on social media platforms like X (formerly Twitter), LinkedIn, and Facebook.

Ardelyx, Investors, Conferences